期刊文献+

阿尔茨海默病患者中胰岛素与β样淀粉蛋白的关系 被引量:2

The association of insulin and plasma concentration of β-amyloid in Alzheimer's disease.
下载PDF
导出
摘要 目的 研究阿尔茨海默病(AD)患者外周血胰岛素与β样淀粉蛋白水平的关系。方法 患者为上海市1997-1998年的痴呆流行病学调查中的确诊病例,对照组为病例组的同社区居民,测定外周血的胰岛素与β样淀粉蛋白水平。结果 AD组的胰岛素水平(25.56±19.12μIU/mL)高于正常对照(15.88±11.05μIU/mL),两组相比有显著性差异(H=10.5,P<0.05),AD组β样淀粉蛋白水平(21.24±9.4 pg/mL)也高于对照(16.03±7.25 pg/mL)两组相比有显著性差异(H=13.1,P<0.05),随年龄的增长,90岁以前β样淀粉蛋白的量无明显变化,AD组与对照组的胰岛素量都呈下降趋势。β样淀粉蛋白与胰岛素(偏回归系数0.017,P>0.05)和年龄(偏回归系数0.082,P>0.05)差异没有显著性。结论 AD患者胰岛素水平与β样淀粉蛋白水平有关。 Objective To study the association of insulin and the plasma concentration of β-amyloid in Alzheimer's disease (AD). Methods All cases were participants who were diagnosed in the investigation in Shanghai between 1997 and 1998. The concentration of plasma insulin and β-amyloid were tested by radiological immunology analysis. Results Patients with AD had higher insulin level (25.56±19.12 μIU/mL) than normal control group (15.88 ± 11.05 μIU/mL), There was significantly different between the two group ( H = 10.5,P<0.05). Compared with control group, patients with AD had higher β-amyloid level (21.24±9.4 pg/mL) than normal control group (16.03±7.25 pg/mL)。 There was significantly different between the two groups (H=13.1, P<0.05). There's no statistical significance between the β-amyloid level and insulin ( r = 0.017, P>0.05)or age ( r =0.082, P > 0.05). Conclusions There was association between insulin and β-amyloid concentration in Alzheimer's disease.
出处 《中国神经精神疾病杂志》 CAS CSCD 北大核心 2003年第1期24-26,共3页 Chinese Journal of Nervous and Mental Diseases
基金 国家九五攻关课题(编号:96-906-05-01)
关键词 阿尔茨海默病 胰岛素 β样淀粉蛋白 Alzheimer's disease Insulin β-amyloid
  • 相关文献

参考文献13

  • 1[1]Tokuda T, Fukushima T, Ikeda S, et al. Plasma levels of β-proteins Aβ1-40, Aβ1-42(43)are elevated in Down's syndrome. Ann Neurol, 1997, 41(2): 271.
  • 2[2]Craft S, Peskind E, Schwartz M. W., et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology, 1998, 50( 1 ): 164.
  • 3[3]Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of B-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol, 1995, 38(4): 643.
  • 4[4]Tomaoka A, Sawamura N, Fukushima T, et al. Amiloid B-protein42(43) in cerebrospinal fliud of patients with Alzheimer's disease. J Neurol Sci, 1997, 148(10) :41.
  • 5[5]Ott A, Stolk BP, van Harskamp F, et al. Diabetes mellitus and risk of dementia: The Rotterdam study. Neurology, 1999, 53(9): 1937.
  • 6[6]Kurochkin Ⅳ, Goto S. Alzheimer's beta-amyloid peptide specifically in- teracts with and is degraded by insulin degrading enzyme. FEBS Lett, 1994, 345(1): 33.
  • 7[7]Perez A, Morelli L, Cresto JC. Degradation of soluble amyloid beta-pep- tides 1-40, 1-42, and the Dutch variant 1-40 Q by insulin degrding en zyme from Alzheimer disease and control brains. Neurochem Res, 2000, 25(2) :247.
  • 8[8]Vekrellis K, Ye Z, Qiu WQ, et al. Neurons regulate extracellular levels of myloid-protein via proteolysis by insulin-degrading enzyme. J Neurosci, 2000, 20(5): 1657.
  • 9[9]Xie L, Helmerhorst E, Taddei K. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. Neurosci, 2002, 22 (10): RC 221.
  • 10[10]Meneilly GS, Hill A. Alternation in glucose metabolism in patients with Alzheimer's disease. J Am Geriatr Soc, 1993, 41(7): 710.

同被引文献23

引证文献2

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部